PEX19

Across TCGA pan-cancer cohorts, PEX19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PEX19 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEX19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PEX19 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, GBM, and UCEC are the cancer types where PEX19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.625	0.436	.007	13	view →
GBM	OS	Quartile	All	0.519	0.892	.008	5	view →
UCEC	OS	Tertile	III,IV	1.000	0.403	.032	4	view →
CCRCC	DFS	Tertile	All	0.619	0.837	.014	2	view →
LUAD	OS	Median	All	0.906	0.787	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PEX19–PDAC (OS)

Open the PDAC breakdown →